CA Patent

CA3105552C — Androgen receptor modulator and uses thereof

Assigned to Aragon Pharmaceuticals Inc · Expires 2023-06-27 · 3y expired

What this patent protects

There is described herein a pharmaceutical composition comprising a nonaqueous, lipid-based solution of the compound of Formula (I) in a softgel capsule, wherein the composition comprises the compound of Formula (I), vitamin E d-.alpha.-tocopheryl polyethylene glycol 1000 succina…

USPTO Abstract

There is described herein a pharmaceutical composition comprising a nonaqueous, lipid-based solution of the compound of Formula (I) in a softgel capsule, wherein the composition comprises the compound of Formula (I), vitamin E d-.alpha.-tocopheryl polyethylene glycol 1000 succinate NF (Vitamin E TPGS), polyethylene glycol 400 NF/EP (PEG 400), glycerol monocaprylocaprate EP and caprylocaproyl macroglycerides EP/NF (see formula I)

Drugs covered by this patent

Patent Metadata

Patent number
CA3105552C
Jurisdiction
CA
Classification
—
Expires
2023-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Aragon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.